Jump to ContentJump to Main Navigation
Show Summary Details

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

1 Issue per year


IMPACT FACTOR increased in 2015: 0.190
5-year IMPACT FACTOR: 0.221

SCImago Journal Rank (SJR) 2015: 0.140
Source Normalized Impact per Paper (SNIP) 2015: 0.154
Impact per Publication (IPP) 2015: 0.197

Open Access
Online
ISSN
2391-5463
See all formats and pricing
Volume 5, Issue 2 (Apr 2010)

Issues

Antimicrobial activity of Ankaferd Blood Stopper® against nosocomial bacterial pathogens

Zeynep Saribas
  • Department of Microbiology and Clinical Microbiology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey
  • Email:
/ Burcin Sener
  • Department of Microbiology and Clinical Microbiology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey
  • Email:
/ Ibrahim Haznedaroglu
  • Department of Hematology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey
  • Email:
/ Gulsen Hascelik
  • Department of Microbiology and Clinical Microbiology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey
  • Email:
/ Serafettin Kirazli
  • Department of Research and Development, Ankaferd Drug Inc., 34820, Istanbul, Turkey
  • Email:
/ Hakan Goker
  • Department of Hematology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey
  • Email:
Published Online: 2010-04-17 | DOI: https://doi.org/10.2478/s11536-009-0140-4

Abstract

The aim of this study is to investigate the in vitro antimicrobial activity of Ankaferd Blood Stopper® against methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus species, Escherichia coli, Pseudomonas species, Acinetobacter species and Klebsiella species of nosocomial origin. Ankaferd inhibited growth in 72.4% to 100% of the bacteria tested, depending on the type of the isolate. As a result, it can be stated that Ankaferd inhibits the in vitro growth of nosocomial bacteria. This is a novel, important finding since severe hospital infections coexist with many hemostatic disorders, and the use of Ankaferd may increase hemostatic potential in such clinical conditions.

Keywords: Ankaferd Blood Stopper®; Antibacterial activity; Nosocomial infection; Hemostatic agent

  • [1] Goker H., Haznedaroglu I.C., Ercetin S., Kirazli S., Akman U., Ozturk Y., Firat, H.C. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper, J. Int. Med. Res., 2008, 36, 163–170

  • [2] www.ankaferd.com

  • [3] Arslan S., Haznedaroglu I.C., Oz B., Goker, H., Endobronchial application of Ankaferd blood stopper to control profuse lung bleeding leading to hypoxemia and hemodynamic instability, Respir. Med., 2009, 2, 144–146

  • [4] Dogan O.F., Ozyurda U., Uymaz O.K., Ercetin S., Haznedaroglu I. New anticoagulant agent for CABG surgery, Eur J Clin Invest, 2008, 38, 341–341 http://dx.doi.org/10.1111/j.1365-2362.2008.1943_1.x [Crossref]

  • [5] Ibis M., Kurt M., Onal I.K., Haznedaroglu I.C., Successful management of bleeding due to solitary rectal ulcer via topical application of Ankaferd blood stopper, J Altern Complement Med, 2008, 14, 1073–1074 http://dx.doi.org/10.1089/acm.2008.0314 [Crossref] [Web of Science]

  • [6] Kurt M., Disibeyaz S., Akdogan M., Sasmaz N., Aksu S., Haznedaroglu I.C., Endoscopic application of ankaferd blood stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: a case report. Am J Gastroenterol, 2008, 103, 2156–2158 http://dx.doi.org/10.1111/j.1572-0241.2008.01982_15.x [Crossref]

  • [7] Kurt M., Kacar S., Onal I.K., Akdogan M., Haznedaroglu I.C., Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract, Endoscopy, 2008, 40, E262 http://dx.doi.org/10.1055/s-2008-1077648 [Crossref]

  • [8] Ucar Albayrak C., Caliskan U., Haznedaroglu I.C., Goker H, Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper [Letter and Response], J Int Med Res, 2008, 36, 1447–1449

  • [9] Akar N., Demiralp D.O., Haznedaroglu I.C., Goker H, Functional Proteomics of Ankaferd Blood Stopper, Blood, 2008, 112, 4103

  • [10] Yılmaz E., Gulec S., Haznedaroglu I.C., Akar N, Effects of Ankaferd on HUVEC transcription factors and erythrocyte protein profile, In: Haznedaroglu I.C., Goker H., Ozdemir O., Kosar A., Firat H. (Eds.), Ankaferd: Scientific Perspectives and Basic-Clinical Data. Naviga Publications, Istanbul, 2008., 60

  • [11] Akkoc N., Akcelik M., Haznedaroglu I., Goker H., Aksu S., Kirazli S., Firat H. In vitro anti-bacterial activities of Ankaferd Blood Stopper, Int J Lab Hematol, 2008, 30, 95–95 http://dx.doi.org/10.1111/j.1751-553X.2008.01027.x [Crossref]

  • [12] Goker H., Cetinkaya D., Kilic E., Haznedaroglu I.C., Kirazli S., Firat H. Anti-cancer activity of Ankaferd Blood Stopper on osteosarcom (SAOS-2) cell lines in vitro, In: Haznedaroglu I.C., Goker H., Ozdemir O, Kosar A, Firat H, (Eds.), Ankaferd: Scientific perspectives and basic-clinical data. Naviga Publications, Istanbul, 2008, 109

  • [13] Goker H., Kilic E., Cetinkaya D., Buyukasik Y., Aksu S., Turgut M., Haznedaroglu I. Anti-cancer activity of Ankaferd on human colon cancer (CACO-2) in vitro, In: Haznedaroglu I.C., Goker H., Ozdemir O., Kosar A., Firat H. (Eds.), Ankaferd: Scientific Perspectives and Basic-Clinical Data, Naviga Publications, Istanbul, 2008, 108

  • [14] Tasdelen Fisgin N., Tanriverdi Cayci Y., Coban A.Y., Ozatli D., Tanyel E., Durupinar, B., Tulek N, Antimicrobial activity of plant extract Ankaferd Blood Stopper, Fitoterapia, 2009, 80, 48–50 http://dx.doi.org/10.1016/j.fitote.2008.09.006 [Crossref] [Web of Science]

  • [15] Corriere M.D., Decker C.F., MRSA: An evolving pathogen, Dis. Mon., 2008, 54, 751–755 http://dx.doi.org/10.1016/j.disamonth.2008.09.007 [Crossref]

  • [16] Gleeson T.D., Prevention and control of methicillinresistant Staphylococcus aureus., Dis. Mon., 2008, 54, 801–806 http://dx.doi.org/10.1016/j.disamonth.2008.09.009 [Crossref]

  • [17] Jeon M.H., Choi S.H., Kwak Y.G., Chung J.W., Chung J.W., Lee S.O., Jeong J.Y., Woo J.H., Kim Y. S., Risk factors for the acqusition of carbapenemresistant Escherichia coli among hospitalized patients. Diag. Microb. Infect. Dis., 2008, 62, 402–406 http://dx.doi.org/10.1016/j.diagmicrobio.2008.08.014 [Crossref]

  • [18] Kang C.I., Kim S.H., Bang J.W., Kim H.B., Kim N.J., Kim E. C., Oh M., Choe K. W. Communityacquired versus nosocomial Klebsiella pneumoniae bacteremia: Clinical features, treatment outcomes, and clinical implication of antimicrobial resistance, J. Korean Med. Sci., 2006, 21, 816–822 http://dx.doi.org/10.3346/jkms.2006.21.5.816 [Crossref] [Web of Science]

  • [19] Lagamayo E.N., Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries, Am. J. Infect. Control 2008, 36(Suppl 4), S101–108 http://dx.doi.org/10.1016/j.ajic.2007.10.020 [Crossref]

  • [20] Peleg A.Y., Seifert H., Paterson D.L., Acinetobacter baumannii: Emergence of a successful pathogen, Clin. Microb. Rev., 2008, 21, 538–582 http://dx.doi.org/10.1128/CMR.00058-07 [Crossref]

  • [21] Slama T.G., Gram-negative antibiotic resistance: there is a price to pay, Crit Care, 2008, 12(Suppl 4), 12, 233 [Crossref]

  • [22] Taconelli E., Cataldo M.A., Vancomycin-resistant enterococci (VRE): transmission and control, Int. J. Antimicrob. Agents, 2008, 31, 99–106 http://dx.doi.org/10.1016/j.ijantimicag.2007.08.026 [Crossref]

  • [23] Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing, CLSI document M100-S18 (2008)

  • [24] Turel I., Sonc A., Zupancic M., Sepcic K., Turk T., Biological activity of some magnesium (II) complexes of quinolones, Med. Based Drugs, 2000, 7, 101–104 http://dx.doi.org/10.1155/MBD.2000.101 [Crossref]

  • [25] Tepe B., Donmez E., Unlu M., Candan F., Daferera D., Unlu-Vardar G., Polissiou M., Somken A., Antimicrobial and antioxidative activities of essential oils and methanol extracts of Salvia cryptantha (Montbret et Aucher ex Benth.) and Salvia multicaulis (Vahl) Food Chemistry, 2004, 84, 519–525 [Crossref]

  • [26] Bilgili H., Koşar A., Kurt M., Önal İ.K., Göker H., Çaptuğ Ö., Kekilli M., Turgut M., Kirazlı Ş., Aksu S., Haznedaroğlu, I.C., Hemostatic effects of Ankaferd in a swine bleeding model. Medical Principles Pract., 2009, 18, 165–169 http://dx.doi.org/10.1159/000204344 [Crossref]

  • [27] Cipil H., Kosar A., Kaya A., Uz B., Haznedaroglu I.C., Goker H., Ozdemir O., Koroglu M., Kirazli S., Firat, H., In Vivo Hemostatic Effect of the Medicinal Plant Extract Ankaferd Blood Stopper in Rats Pretreated With Warfarin, Clin. Appl. Thromb. Hemost., Clin Appl Thromb Hemost. 2009 May–Jun;15(3):270–276 http://dx.doi.org/10.1177/1076029608329578 [Crossref] [Web of Science]

  • [28] Kosar A., Cipil H., Kaya A., Uz B., Haznedaroglu I.C., Goker H., Ozdemir O., Ercetin S., Kirazli S., Firat, H., The efficacy of Ankaferd Blood Stopper in antithrombotic drug induced primary and secondary hemostatic abnormalities of a rat bleeding model, Blood Coagul. Fibrinolysis, 2009, 20, 185–190 http://dx.doi.org/10.1097/MBC.0b013e32831c4cb0 [Crossref] [Web of Science]

  • [29] Buyukasik Y., Sayinalp N., Arici M., Haznedaroglu I.C., Ozcebe O.I., Dundar, S., Penile gangrene in lung cancer, Postgrad. Med. J., 1997, 73, 589–590 http://dx.doi.org/10.1136/pgmj.73.863.589 [Crossref]

  • [30] Ozturk M.A., Haznedaroglu I.C., Ozturk M.H., Ozcebe O., Yucel O.T., Akyol U., Nasopharyngeal angiofibroma in a patient with haemophilia A: a bleeding tumour in a bleeding-prone patient, Haemophilia, 1999, 5, 207–208 http://dx.doi.org/10.1046/j.1365-2516.1999.00296.x [Crossref]

  • [31] Soylu A.R., Buyukasik Y., Cetiner D., Buyukasik N.S., Koca E., Haznedaroglu I.C., Ozcebe O.I., Simsek H., Overt gastrointestinal bleeding in haematologic neoplasms, Dig. Liver Dis., 2005, 37, 917–922 http://dx.doi.org/10.1016/j.dld.2005.07.017 [Crossref]

About the article

Published Online: 2010-04-17

Published in Print: 2010-04-01


Citation Information: Open Medicine, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-009-0140-4. Export Citation

© 2009 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Yusuf Kenan Coban, Elif Ozerol, Kevser Tanber, Serkan Erbatur, Ahmet Hamdi Aytekin, and Cemal Fırat
Surgical Science, 2011, Volume 02, Number 01, Page 16
[2]
Alan N. Barkun, Sarvee Moosavi, and Myriam Martel
Gastrointestinal Endoscopy, 2013, Volume 77, Number 5, Page 692
[3]
Emre Huri, Yavuz Beyazit, Rashad Mammadov, Sila Toksoz, Ayse B. Tekinay, Mustafa O. Guler, Huseyin Ustun, Murat Kekilli, Mumtaz Dadali, Tugrul Celik, Müzeyyen Astarci, and Ibrahim C. Haznedaroglu
International Journal of Biomaterials, 2013, Volume 2013, Page 1
[4]
Goksel Leblebisatan, Ali Bay, Suleyman C. Karakus, Murat Kekilli, and Ibrahim C. Haznedaroglu
Blood Coagulation & Fibrinolysis, 2012, Volume 23, Number 6, Page 494
[5]
Berat Z. Haznedaroglu, Yavuz Beyazit, Sharon L. Walker, and Ibrahim C. Haznedaroglu
Critical Reviews in Oncology/Hematology, 2012, Volume 83, Number 1, Page 21
[6]
Sevgi Ciftci, Fahriye Keskin, Sema Keceli Ozcan, Mehmet Ali Erdem, Burak Cankaya, Recep Bingol, and Cetin Kasapoglu
Current Therapeutic Research, 2011, Volume 72, Number 3, Page 120

Comments (0)

Please log in or register to comment.
Log in